Century Therapeutics, Inc. (IPSC) vs Nautilus Biotechnolgy, Inc. (NAUT)

A side-by-side comparison of Century Therapeutics, Inc. and Nautilus Biotechnolgy, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — IPSC vs NAUT

growth of $100 · dividends reinvested · last 5y
IPSC -93.5% (-42.1%/yr)NAUT -80.8% (-28.1%/yr)NAUT compounded faster over this window
050100Start $10020222023202420252026$6$19
IPSC NAUT

IPSC vs NAUT: by the numbers

  • •IPSC is the larger company ($249M vs $247M market cap).
  • •Both run net losses; IPSC's is the smaller (-8.78% vs -29747.89% net margin).

Metrics side by side

Valuation

MetricIPSCNAUT
P/S ratioN/A1299.34
P/B ratio1.071.88

Profitability

MetricIPSCNAUT
Gross margin88.00%0.00%
Operating margin-13.78%0.00%
Net margin-8.78%-29747.89%
ROE-47.25%-43.11%
ROIC-43.69%-40.52%

Growth (annualized)

MetricIPSCNAUT
Total return CAGR (5Y)-42.05%-20.56%

Frequently asked

How have IPSC and NAUT total returns compared?
Over the past 5 years, IPSC delivered -42.05% and NAUT delivered -20.56% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.